| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1130-1406(08)70025-1 |
| P698 | PubMed publication ID | 18473502 |
| P50 | author | Guillermo Quindós Andrés | Q43182008 |
| P2093 | author name string | Elena Eraso | |
| Guillermo Quindós | |||
| P2860 | cites work | Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. | Q24537282 |
| In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole | Q24538858 | ||
| Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 | Q28260910 | ||
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts | Q28368930 | ||
| In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients | Q28376042 | ||
| In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species | Q28379527 | ||
| Fungal ß(1,3)-D-glucan synthesis | Q29030521 | ||
| Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 | ||
| Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program | Q30445376 | ||
| Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 | ||
| [In vitro antifungal activity of voriconazole: New data after the first years of clinical experience]. | Q31129662 | ||
| Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. | Q31440064 | ||
| Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. | Q33210615 | ||
| Anidulafungin: a new echinocandin with a novel profile | Q33222148 | ||
| Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance | Q33258644 | ||
| Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis | Q33803108 | ||
| A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis | Q45096984 | ||
| Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis | Q45108767 | ||
| Initial results from a longitudinal international surveillance programme for anidulafungin (2003). | Q45162980 | ||
| Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital | Q45223627 | ||
| In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi | Q46390314 | ||
| In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula | Q46450174 | ||
| Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole | Q46740583 | ||
| Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus | Q46851213 | ||
| Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets | Q46855387 | ||
| Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre. | Q46870024 | ||
| Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis | Q46933146 | ||
| Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient | Q46971624 | ||
| Candidemia in neonatal intensive care units: Barcelona, Spain. | Q50777995 | ||
| Virulence of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis in reconstituted human tissue models. | Q51036518 | ||
| Candidemia in pediatric patients with congenital heart disease. | Q51245188 | ||
| Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. | Q54251847 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center | Q57269730 | ||
| Mucormycosis: an emerging disease? | Q57569311 | ||
| Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp | Q77474976 | ||
| Species distribution and antifungal susceptibility patterns of Candida spp. bloodstream isolates from a Brazilian tertiary care hospital | Q79864121 | ||
| Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis | Q80374897 | ||
| In vitro activity of micafungin combined with itraconazole against Candida spp | Q80795198 | ||
| Susceptibility patterns of Candida species recovered from Canadian intensive care units | Q81298833 | ||
| One year prospective survey of Candida bloodstream infections in Scotland. | Q33910250 | ||
| Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases | Q34404335 | ||
| Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 | ||
| Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase | Q34576400 | ||
| Anidulafungin versus fluconazole for invasive candidiasis | Q34580316 | ||
| Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. | Q34680777 | ||
| Candidemia in Norway (1991 to 2003): results from a nationwide study | Q34719299 | ||
| Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy | Q34721774 | ||
| Candida dubliniensis, a new fungal pathogen | Q34732978 | ||
| Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. | Q35641428 | ||
| Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. | Q35714132 | ||
| Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds | Q35913719 | ||
| Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature | Q36327963 | ||
| Candidaemia in Europe: epidemiology and resistance | Q36463475 | ||
| Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations | Q36491819 | ||
| Anidulafungin: a novel echinocandin | Q36508916 | ||
| Aspergillosis: spectrum of disease, diagnosis, and treatment | Q36598035 | ||
| The echinocandins | Q36742397 | ||
| A comparative evaluation of properties and clinical efficacy of the echinocandins | Q36895839 | ||
| In vitro activity of anidulafungin against selected clinically important mold isolates | Q37734590 | ||
| In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. | Q39077602 | ||
| In vitro interactions of approved and novel drugs against Paecilomyces spp. | Q40967988 | ||
| In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. | Q41772012 | ||
| In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. | Q41810114 | ||
| Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. | Q41842788 | ||
| Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro | Q42100410 | ||
| In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. | Q42112008 | ||
| In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species | Q42171162 | ||
| Lack of pharmacokinetic interaction between anidulafungin and tacrolimus | Q42612968 | ||
| In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. | Q42949201 | ||
| In vitro susceptibility of Candida dubliniensis to current and new antifungal agents | Q43651355 | ||
| In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms | Q43868191 | ||
| Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods | Q44019731 | ||
| In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens | Q44120429 | ||
| Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death | Q44235994 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method | Q44257296 | ||
| In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. | Q44340936 | ||
| Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases | Q45015455 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 83-91 | |
| P577 | publication date | 2008-06-01 | |
| P1433 | published in | Revista iberoamericana de micologia | Q27719516 |
| P1476 | title | In vitro antifungal activity of anidulafungin | |
| P478 | volume | 25 |
Search more.